Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a single institution, open label, phase II study in androgen-independent prostate
cancer patients who are chemotherapy-naïve. Patients will receive Revlimid® 25 mg daily on
Days 1-21 followed by 7 days of rest repeated every 28 days. Treatment continues until
disease progression, patient's withdrawal, unacceptable toxicity or the investigator's
discretion.